Skip to main content

Advertisement

SpringerLink
Log in

Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Paridaens R et al. (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14: 1391–1398

    Article  CAS  Google Scholar 

  2. Buzdar AU et al. (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase II trials. Cancer 83: 1142–1152

    Article  CAS  Google Scholar 

  3. Dombernowsky P et al. (1998) Letrozole, a new oral aramatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453–461

    Article  CAS  Google Scholar 

  4. Baum M et al. (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802–1810

    Article  CAS  Google Scholar 

  5. Boccardo F et al. (2003) Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. [abstract] Breast Cancer Res Treat 82 (Suppl): s6

    Google Scholar 

  6. Goss PE et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Lisa Hutchinson, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Editor of Nature Clinical Practice Oncology,

    Lisa Hutchinson

Authors
  1. Lisa Hutchinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa Hutchinson.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hutchinson, L. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?. Nat Rev Clin Oncol 1, 24–25 (2004). https://doi.org/10.1038/ncponc0021

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0021

  • Springer Nature Limited

Search

Navigation